Measuring convertase levels in pancreatic adenocarcinoma tumors and blood

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This prospective, single-centre observational cohort will collect tumor (primary or metastatic) and same-day blood samples from adults undergoing biopsy or pancreatic/metastasis surgery at Institut Bergonié. Samples will be analyzed for expression levels of convertases and correlated with standard clinical and pathological data. Patients will be followed for two years with routine radiological checks to record first progression and vital status. No experimental treatments are given; inclusion requires available malignant tumor tissue, WHO performance status 0–2, and informed consent.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years.
2. Pancreatic adenocarcinoma (suspected on radiological assessment or histologically proven):

   1. Indication for biopsy of metastasis(es) performed as part of standard care for patients who already have a histologically confirmed diagnosis of pancreatic cancer.
   2. Indication for pancreatic surgery or metastasis(es) carried out as part of standard care for patients with a suspicion of pancreatic cancer on radiological assessment or who already have a confirmed histological diagnosis of pancreatic cancer.
3. Whatever the stage of the disease.
4. Whatever the type of treatment proposed (systemic, surgery, radiotherapy, etc.).
5. Patient who has never received systemic treatment or advanced radiotherapy.
6. WHO 0-1-2.
7. Life expectancy \> 3 months.
8. Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research).
9. Patient affiliated to a social security scheme in compliance with Article 1121-11 of the French Public Health Code.

Exclusion Criteria:

1. Indication for biopsy for primary diagnosis of pancreatic cancer
2. No indication for treatment of pancreatic cancer.
3. Adjuvant/neoadjuvant chemotherapy completed less than 6 months ago in the case of patients with recurrent disease.
4. Patient already included in the study.
5. Geographical, social or psychological factors rendering the patient unable to undergo study monitoring and procedures.

Where it's running

• Institut Bergonié, Comprehensive Cancer Center
  Bordeaux, France Recruiting

Study contacts

• Principal investigator: Simon PERNOT, Dr — Institut Bergonié
• Study coordinator: Simon PERNOT, Dr
• Email: s.pernot@bordeaux.unicancer.fr
• Phone: +33556333347

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Liquid biopsy biomarkers to detect and monitor pancreatic cancer

  Researchers test blood-based microRNA signals to see if they can identify pancreatic cancer risk or early disease in people with familial or hereditary risk or mucinous cysts.

  Recruiting Università Vita-Salute San Raffaele · Milan, MI · NCT07700992

• INSPIRE: Putting patient-reported info into multidisciplinary tumor boards

  This study tests whether adding electronic patient-reported outcomes to tumor board discussions can help guide treatment decisions for women with breast, gynecologic, pancreatic cancers and related cancers.

  Recruiting University of Alabama at Birmingham · Birmingham, Alabama and 2 other locations · NCT07671937

• MRI scan for detecting pancreatic cancer in people at high risk

  This study tests a dedicated pancreas MRI (MRP) tool to see if it helps find pancreatic cancer earlier in people with a strong family or genetic risk.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07612046

• Cutting down ultra-processed foods for people at high cancer risk

  This project tests whether using the Open Food Facts smartphone app alongside nutrition education helps adults at high risk of cancer eat fewer ultra-processed foods.

  Recruiting at 2 sites Gustave Roussy, Cancer Campus, Grand Paris · Avignon and 2 other locations · NCT07436312

• Carbon nanoparticle‑loaded iron for advanced solid tumors

  This test uses direct injections of a carbon nanoparticle‑loaded iron medicine (CNSI‑Fe) to see if it can shrink tumors in adults with advanced solid cancers who have no effective standard treatment options.

  Recruiting at 4 sites Phase 1/2 Sichuan Enray Pharmaceutical Sciences Company · Beijing, Beijing Municipality and 8 other locations · NCT07433283

• Axelopran for adults with advanced breast, lung, pancreas, or prostate cancer who take opioids

  This trial will test whether taking axelopran can slow tumor progression, help bowel problems, and reduce inflammation in adults with advanced breast, lung, pancreas, or prostate cancer who are using opioid pain medicines.

  Recruiting at 2 sites Phase 2 HealthPartners Institute · Saint Louis Park, Minnesota and 1 other locations · NCT07354919

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.